Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
November 07 2023 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
| ☐ |
Preliminary Proxy Statement |
| ☐ |
Confidential, for Use of
the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ |
Definitive Proxy Statement |
| ☒ |
Definitive Additional Materials |
| ☐ |
Soliciting Material Pursuant
to §240.14a-12 |
AgeX
Therapeutics, Inc.
(Name
of Registrant as Specified in Its Charter)
(Name
of Person(s) Filing Proxy Statement if other than the Registrant)
| Payment of Filing Fee (Check the appropriate
box): |
| ☒ |
No fee required. |
| ☐ |
Fee paid previously with preliminary materials. |
| ☐ |
Fee computed on table in exhibit required by Item 25(b)
per Exchange Act Rules 14a-6(i)(1) and 0-11. |
Dear
AgeX Stockholders,
As we approach the end of 2023, we are enthusiastic about the prospects
for AgeX entering new medical fields by acquiring Serina Therapeutics, Inc. through a merger under the terms of an Agreement and Plan
of Merger and Reorganization that we entered into this past August. Serina currently has a pipeline of small molecule candidates targeting
central nervous system indications, enabled by the company’s proprietary POZ Platform™ delivery technology. In addition to
advancing Serina’s wholly owned pipeline assets, Serina is working with pharma partners currently advancing pre-clinical studies
exploring POZ polymer lipid-nanoparticles or “LNPs” in next generation LNP delivered RNA vaccines. Serina’s current
therapeutic focus includes advanced Parkinson’s Disease, post-operative pain indications, and refractory epilepsy. Serina is also
working to expand its LNP and anti-body drug conjugate partnering collaborations.
If
we complete the merger, AgeX will focus primarily on developing Serina’s pipeline of product candidates, and we will seek other
opportunities for our current core cell therapy and induced Tissue Regeneration (iTRTM) platforms. However, we expect that
our subsidiary NeuroAirmid Therapeutics, Inc., which we co-own with certain researchers, will continue to work to advance into clinical
trials neural cells for the treatment of Huntington’s Disease, based on work we sponsored at the University of California –Irvine.
The
merger will bring to fruition a primary objective of our restructuring plans that we announced earlier in the year with the goal of finding
new opportunities for AgeX, including a pipeline of product candidates that are in a more advanced stage of development than those in
AgeX’s legacy core programs. Completion of the merger is subject to the satisfaction of certain conditions, including approval
by AgeX and Serina stockholders. We anticipate that the merger will be finalized in the coming months when you will be invited to a special
meeting to vote. More details will follow in due course.
We
invite you to join us for the Annual Meeting of Stockholders of AgeX Therapeutics, Inc. which will be held on Wednesday, December 13,
2023 at 10:00 a.m. Pacific Time. We will be holding the Annual Meeting this year as a “virtual” meeting by online participation
only at https://web.lumiagm.com/268644388. If you wish to attend the Annual Meeting online you will need to gain admission
in the manner described in the Proxy Statement that accompanies this letter.
Sincerely,
 |
|
| Joanne
M. Hackett, PhD |
|
| Chairwoman
of the Board & Interim CEO |
|
| |
|
| November 7,
2023 |
|
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Nov 2024 to Dec 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Dec 2023 to Dec 2024
